Anji Pharma Secures China Rights to Apo E Mimetic Platform from LipimetiX Development
Lead peptide AEM-28 has demonstrated remarkable VLDL cholesterol and triglyceride reductions in Phase 1 and Phase 2 human clinical trials.
Anji Pharma launches a global strategy to accelerate medicines to China and other markets
Anji Pharma, a new global pharmaceutical company tackling biological targets with exquisite validation from human genetics, launched earlier this year.
1 / 1